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Dynamic metabolic patterns 
tracking neurodegeneration and 
gliosis following 26S proteasome 
dysfunction in mouse forebrain 
neurons
Philippine C. Geiszler1,2, Aslihan Ugun-Klusek3, Karen Lawler4, Marie-Christine Pardon4, Ding 
Yuchun5, Li Bai6, Clare A. Daykin2,7, Dorothee P. Auer1,8 & Lynn Bedford4
Metabolite profiling is an important tool that may better capture the multiple features of 
neurodegeneration. With the considerable parallels between mouse and human metabolism, the use 
of metabolomics in mouse models with neurodegenerative pathology provides mechanistic insight 
and ready translation into aspects of human disease. Using 400 MHz nuclear magnetic resonance 
spectroscopy we have carried out a temporal region-specific investigation of the metabolome of 
neuron-specific 26S proteasome knockout mice characterised by progressive neurodegeneration and 
Lewy-like inclusion formation in the forebrain. An early significant decrease in N-acetyl aspartate 
revealed evidence of neuronal dysfunction before cell death that may be associated with changes in 
brain neuroenergetics, underpinning the use of this metabolite to track neuronal health. Importantly, 
we show early and extensive activation of astrocytes and microglia in response to targeted neuronal 
dysfunction in this context, but only late changes in myo-inositol; the best established glial cell 
marker in magnetic resonance spectroscopy studies, supporting recent evidence that additional early 
neuroinflammatory markers are needed. Our results extend the limited understanding of metabolite 
changes associated with gliosis and provide evidence that changes in glutamate homeostasis 
and lactate may correlate with astrocyte activation and have biomarker potential for tracking 
neuroinflammation.
Neurodegenerative diseases such as Alzheimer’s disease (AD) are complex and the underlying mechanisms 
involved unclear. Studies of neurodegeneration need to temporally capture multiple molecular entities and their 
interactions to advance our knowledge of early disease mechanisms and identify biomarkers that represent patho-
logical processes at a molecular or cellular level. Metabolomics is an important systems approach that can identify 
changes in numerous individual metabolites representing a multitude of functional pathways that may better 
characterise the multiple features of neurodegenerative disease and lead to the development of effective thera-
peutic strategies1–3.
Current paradigms for the cause and progression of major human neurodegenerative diseases indicate that 
abnormal protein aggregation, impaired protein degradation, mitochondrial dysfunction, oxidative stress and 
neuroinflammation are involved in various ways. The ubiquitin proteasome system (UPS); the major pathway 
for the degradation of damaged, misfolded and aggregation-prone proteins, has been linked to neurodegenera-
tive disease since ubiquitin was found in their characteristic protein aggregates4–8. Proteasome activity declines 
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during aging and UPS dysfunction is supported by recent genome-wide association studies in AD9,10. Further, a 
direct role for the UPS in the pathogenic mechanisms of neurodegenerative disease was demonstrated by inacti-
vation of the 26S proteasome in mouse neurons, causing neurodegeneration and Lewy-like inclusions resembling 
human pale bodies11. Autophagy, the other major protein quality control pathway in the cell, was also linked to 
neurodegenerative disease following the observation that loss of autophagy in mouse neurons causes accumu-
lation of ubiquitin-positive aggregates and neurodegeneration, however, a recent study suggests ubiquitinated 
proteins are not major targets for basal autophagy12,13. Mitochondrial dysfunction, particularly altered oxidative 
phosphorylation, has been convincingly associated with disease pathogenesis, and disease-linked proteins shown 
to have a detrimental effect on mitochondrial function and increase reactive oxygen species production14–17. 
Neuroinflammation is increasingly being recognised, not only as a pathological hallmark, but as a contributor to 
neurodegenerative disease, characterised by the reactive morphology of astrocytes and microglia, and release of 
inflammatory mediators18–26. With the considerable parallels between rodent and human metabolism, the meta-
bolic profiles identified in animal models with neurodegenerative pathology directly provide mechanistic insight 
and ready translation to some aspects of human disease.
N-acetyl aspartate (NAA) as one of the most prominent metabolites in 1H magnetic resonance spectroscopy 
(MRS) of the brain is employed as a general indicator of neuronal health, and specifically mitochondrial func-
tion27–31. Clinical studies and experimental models show NAA reduction correlates with neuronal dysfunction 
and neurodegeneration in various neurodegenerative conditions, including Alzheimer’s and Parkinson’s dis-
eases32–35. Our understanding of which metabolite(s) best track neuroinflammation in vivo, however, is lim-
ited18–21. Myo-inositol has been shown to be a glial cell marker with consistent clinical evidence of elevated 
myo-inositol in a range of diseases characterised by astrogliosis36–42. The inferential notion that myo-inositol 
levels detected by in vivo 1H MRS reflect the extent of activation of astrocytes and microglia is less well supported. 
Recent data has been controversial and activation of glia has been associated with glutamate/glutamine, lactate, 
choline-containing compounds as well as macromolecules and lipids36–42.
Using 400 mHz nuclear magnetic resonance (NMR) spectroscopy we have carried out a temporal 
region-specific characterisation of the metabolome of neuron-specific 26S proteasome knockout mice (Psmc1fl/fl; 
CaMKIIα-Cre) between 2 and 6 weeks-old accompanying progressive neurodegeneration and Lewy-like inclu-
sion formation in the forebrain. Importantly, we have combined our NMR spectroscopy analysis with quantitative 
histopathological and molecular investigations of activated astrocytes and microglia in Psmc1fl/fl;CaMKIIα-Cre 
mouse forebrain to inform on putative metabolite changes that may track gliosis.
Materials and Methods
Mice. Psmc1fl/fl;CaMKIIα-Cre and control (Psmc1fl/fl;CaMKIIα-Wt or Psmc1fl/wt;CaMKIIα-Wt) littermate mice 
were housed under identical conditions and genotyped as described previously11. Mice had ad libitum access to 
food and water. Female mice were used in all analyses. Cortex (50 mg), hippocampus (10 mg) and cerebellum 
(30 mg) were rapidly micro-dissected from mouse brain, snap-frozen in liquid nitrogen and transferred directly 
to −80 °C for storage until extraction. Samples were collected at the same time on each day over a period of 
4 months before tissue extraction for 1H NMR Spectroscopy. The number of mice used at each age in NMR 
spectroscopy was determined by power calculations using online software (https://www.stat.ubc.ca/~rollin/stats/
ssize/n2.html) based on unpublished pilot data of n = 3 mice at each age (power 0.80; alpha 0.05). Actual num-
ber of mice used at each age met or exceeded power calculations and is provided in Supplementary Table 1. All 
procedures were authorised and approved by the University of Nottingham ethics committee and carried out in 
accordance with the UK Animals (Scientific Procedures) Act 1986.
Tissue Extraction for 1H NMR Spectroscopy. Frozen tissues (Supplementary Table 1) were extracted 
using a previously recommended chloroform-methanol procedure43. Samples were first homogenised in water 
using a ball mill (2 min, 30/s; Retsch MM 301; Retsch GmbH, Germany). The homogenates were further treated 
with chloroform, methanol and additional water; 8 mL solvent per mg tissue at a final solvent ratio of 2:2:3 
(chloroform:methanol:water)44. After the two liquid extract layers were separated, the solvents were removed 
using a concentrating evaporator system without heating (Jouan RC 10.22; Jouan, France). The hydrophilic 
residues were reconstituted in phosphate-buffered (pH 7.2; 0.1 M) deuterated water containing 3-(trimethylsi-
lyl)-2,2′,3,3′-tetradeuteropropionic acid (TSP; 0.334 nmol/ml) as reference substance prior to their spectroscopic 
analysis.
1H NMR Spectroscopy. Liquid state NMR spectroscopy was performed using a Bruker Avance spectrome-
ter (Bruker BioSpin GmbH, Germany) equipped with a 5 mm SEL probe (1 H/D XYZ-gradient probe) operating 
at a proton frequency of 400.13 MHz. All one-dimensional spectra were recorded at 298.2 K without spinning 
using a conventional water presaturation pulse sequence based on the first increment of a nuclear Overhauser 
effect spectroscopy sequence (32 k data points, spectral width = 13 ppm, number of scans = 128/sample, relaxa-
tion delay = 2 s, mixing time = 0.12 s, acquisition time = 3.15 s).
The TopSpin software (v. 2.1; Bruker BioSpin GmbH, Germany) was used for spectral processing whereby the 
free induction decays (FIDs) were zero-filled to twice the number of data points and apodised by an exponential 
weighing function, applying a line-broadening factor of 0.3 Hz. All spectra were Fourier transformed, phased, 
baseline corrected and calibrated to the TSP reference signal at δ 0.00 ppm.
Spectrum Processing. To prepare the spectral data for pattern recognition analysis, the data points ranging 
from 9.46 to 0.86 ppm, exclusive of solvent signals, were collected into successive 0.04 ppm wide buckets using the 
AMIX software (v. 3.8; Bruker BioSpin GmbH, Germany). To minimise any statistical contribution of tissue mass, 
all spectra were normalised to the total spectral area, i.e. the sum of all included data points.
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Relative quantification of individual metabolites was performed by the sum of their data points in relation to 
the total spectral area, as calculated by the AMIX software. Metabolite quantification was limited to a set of 30 
specific metabolites. Peak annotations, some of which are denoted in Supplementary Fig. 1, were informed by 
the literature3,45,46, in-house and web-based data bases47,48, as well as two-dimensional NMR spectra, such as total 
correlation (TOCSY) and j-resolved spectroscopy (jRES).
Multivariate Statistical Analysis. Data pre-treatment and pattern recognition analysis were performed 
using SIMCA-P (v. 11.0.0.0; Umetrics AB, Sweden). The bucketed dataset was pre-treated by mean-centring with 
and without scaling to unit variance in order to separately investigate the contribution of small and large signals 
to the statistical models.
Principal component analysis (PCA) was performed to obtain information about major trends within data-
sets49. PCA is a method to reduce the complexity of multidimensional datasets, such as spectra, to a few latent 
variables termed principal components (PCs). Projections of the original spectral data onto the newly calculated 
PCs (‘scores plots’) allow the observation of sample clusters illustrating spectral similarities between samples. 
The corresponding ‘loadings plots’ enable the metabolic interpretation of such clusters49. The PCA results were 
assessed through the parameter R2X(cum) describing the amount of spectral data variation explained by the PCs.
Projection to latent structures by partial least squares (PLS) regression and discriminant analysis (PLS-DA) 
were deployed to define distinct group clusters relating to animal age and genotype, respectively. The spectral data 
(so-called ‘X’-block) is related to the ‘Y’-block, which constitutes of numerical data (e.g. age) in the case of PLS 
regression analysis or two categorical groups (e.g. Psmc1fl/fl;CaMKIIα-Cre and control) in the case of PLS-DA, in 
order to inform about the robustness of their relationship as well as X’s predictability of Y. For further details on 
the PLS regression and PLS-DA as well as validation see supplementary experimental information.
Univariate Statistical Analysis. Similar to previous studies, Kolmogorov-Smirnov tests demonstrated that 
the endogenous metabolites in our study did not show Gaussian distribution50. Therefore, Mann-Whitney-U 
tests and the Z-statistic51 were applied to compare individual metabolite concentrations between the two gen-
otypes. Spearman correlation coefficients rμ and rμμ signified the relationship between metabolite concentra-
tion and age or another metabolite concentration, respectively. To minimise the risk of spurious positive results, 
Bonferroni-corrected p values were used.
Immunoblotting. Mouse cortices were homogenised in lysis buffer [50 mM Tris, 150 mM NaCl, 2 mM 
EDTA, 1 mM MgCl2, 100 mM NaF, 10% glycerol, 1% triton X-100, 1% Na deoxycholate, 0.1% SDS, 125 mM 
sucrose and 1% (v/v) protease inhibitor cocktail] using a bead beater (MP bio FastPrep®-24). Samples were cen-
trifuged at 10 000 g for 10 minutes at 4 °C. Subcellular fractionation of mouse cortices (100 mg) was performed 
on ice as described previously52. Freshly dissected cortices were homogenised in buffered sucrose solution [2 mM 
HEPES pH 7.4, 210 mM mannitol, 70 mM sucrose, 0.1 mM EDTA, 1% (v/v) protease inhibitor cocktail] using a 
Dounce tissue grinder to produce total homogenates. Total homogenates were centrifuged at 500 g followed by 
1000 g for 10 min each and the resulting pellet termed the nuclear-enriched fraction. Supernatants were centri-
fuged at 7000 g for 10 min to produce the cytosolic fraction. Following washing in buffered sucrose solution the 
pellet was re-suspended and layered onto a 60, 32, 23 and 15% sucrose gradient in 10 mM MOPS (pH 7.2), 1 mM 
EDTA. Gradients were centrifuged at 130 000 g for 60 min and mitochondria were collected from the 32–60% 
interface. Mitochondria were pelleted by centrifugation at 10 000 g for 10 min and washed twice with buffered 
sucrose solution before re-suspending in buffered sucrose solution for storage; all fractions were stored at −80 °C. 
Protein concentration was determined using Bradford protein assay.
Equal protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by transfer 
to nitrocellulose membrane. Membranes were blocked in 5% dried skimmed milk in Tris-buffered saline (TBS) 
containing 0.1% (v/v) Tween-20 (TBS-T) for 1 h and then incubated overnight at 4 °C with glial fibrillary acidic 
protein (1:4000; Sigma G3893), glutamate dehydrogenase 1 (1:1000; VWR 89379–724), glycogen phosphoryl-
ase (brain form) (1:1000; GeneTex GTX104291), pyruvate dehydrogenase E1 component subunit alpha (1:1000; 
Abcam ab110334), neuron-specific nuclear protein (1:1000; Abcam ab177487) or glyceraldehyde 3-phosphate 
dehydrogenase (1:20 000; Sigma G9545) antibodies in blocking solution. Membranes were washed and incubated 
for 1 h at room temperature with appropriate LI-COR IRDye® 800CW secondary antibodies in TBS (LI-COR 
926-32210 and 926-32211). Bands were visualised using the Odyssey infrared imaging system at 800 nm and 
intensity quantified using the Odyssey Image Studio (LI-COR Biosciences).
Immunohistochemistry. Mice were perfusion-fixed with 0.9% saline followed by 4% paraformaldehyde 
in phosphate buffered saline (pH 7.4). Fixed brains were processed to paraffin and 7 µm horizontal sections cut 
using a microtome. Immunostaining of ionized calcium-binding adapter molecule 1 (1:200; Wako 019-19741), 
glial fibrillary acidic protein (1:200; Sigma G3893), cytochrome c oxidase (1:200; Cell Signalling 4844), gluta-
mate dehydrogenase 1 (1:100; GeneTex GTX105765) and glycogen phosphorylase (brain form) (1:60; GeneTex 
GTX104291) was performed as directed in Vector Laboratories M.O.M Immunodetection (PK2200) or Vectastain 
Elite Rabbit IgG ABC kits (PK6101) using 0.01 M citrate buffer containing 0.05% (v/v) Tween-20 (pH 6) for 
antigen retrieval. Immunostained slides were scanned using a Nanozoomer Digital slide scanner (Hamamatsu 
Photonics) at 40 × magnification and images were viewed using NDP.view2 viewing software.
For quantitation of COXIV-positive aggregates in Psmc1fl/fl;CaMKIIα-Cre neurons annotation tools in 
NDP.view2 viewing software were used to delineate a 1.4 mm2 area including all cortical layers as shown in 
Supplementary Fig. 9. Counting was performed manually in ImageJ.
Semi-automated analysis of Iba1 immunohistochemistry. This was carried out as described pre-
viously42. Levelled Iba1-stained slides were scanned using a Nanozoomer Digital slide scanner (Hamamatsu 
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Photonics) at 40 × magnification. Using custom made software programmed in MATLAB a region of interest 
(ROI) was drawn on the digitised images outlining the cortex and feature recognition performed53. Each image 
was inspected and corrected manually to avoid artifacts. Analysis provided the area occupied by microglia soma 
and isolated processes as a percentage of the ROI as well as the soma size.
Statistics. Details of statistical tests and number of biological replicates (n) are provided in the methods, 
figures and table legends.
Results
The Psmc1fl/fl;CaMKIIα-Cre neurodegeneration mouse model has been previously described11. Psmc1, an essential 
ATPase subunit of the 19 S regulatory particle of the 26S proteasome, is inactivated at approximately 2 weeks-old 
in mouse forebrain neurons by conditional gene targeting using CamKIIα-driven Cre recombinase, causing pro-
gressive 26S proteasome dysfunction between 2 and 4 weeks-old54–57. An elegant study describing species chro-
nometry suggests that the final important steps in mouse brain development occur 29.7 days post-conception 
(postnatal day 12; birth day 0)58. CamKIIα expression is upregulated at approximately 2 weeks-old, allowing 
normal CNS development before Cre-mediated recombination of Psmc1 in post-mitotic neurons. We note the 
limitation that the mice used in this study are juvenile in the biological context of sexual maturity, but we may 
consider the brain to be developed and analyses will have applicability to similar processes in human disease. 
Psmc1fl/fl;CaMKIIα-Cre mice exhibit increasing accumulation of ubiquitinated proteins and paranuclear aggre-
gation of dysfunctional mitochondria from 3 weeks-old52,57. Here, to extend previous data reflecting progressive 
synaptic dysfunction and neurodegeneration, and to correlate with our metabolic profiling analysis we have per-
formed temporal neuron-specific nuclear protein (NeuN) immunoblotting analysis between 2 and 6 weeks-old in 
control and Psmc1fl/fl;CaMKIIα-Cre forebrain; NeuN was not significantly decreased until 5 weeks-old, indicative 
of progressive neurodegeneration following Psmc1 inactivation (Supplementary Fig. 2).
26S proteasome dysfunction in forebrain neurons causes metabolic alterations. This study used 
cortex, hippocampus and cerebellum from control and Psmc1fl/fl;CaMKIIα-Cre mice between 2 and 6 weeks-old. 
The cerebellum served partly as a control for changes in targeted forebrain neurons, but also to reveal any changes 
in ‘other’ brain areas that may be secondary to neurodegenerative processes in the forebrain. Multivariate statisti-
cal analysis of the whole dataset demonstrated clear metabolic differences between brain regions and age groups 
in line with previous reports in rodents (Supplementary Fig. 3, Supplementary Tables 2 and 3)3,46,59,60. Therefore, 
genotypic comparisons were obtained separately for each brain region at each age. The cortex and hippocampus 
of Psmc1fl/fl;CaMKIIα-Cre mice displayed metabolic patterns distinct from controls from 4 weeks-old (Figs 1 
and 2, Table 1, Supplementary Fig. 4). Cortex showed the most pronounced metabolic changes and robust mul-
tivariate statistical models classified all cortical samples from 4, 5 and 6 week-old mice according to their gen-
otype (Supplementary Table 4). Metabolic changes were confirmed by univariate statistical analysis (Fig. 2 and 
Table 1). At 4 weeks-old NAA showed the most significant change in Psmc1fl/fl;CaMKIIα-Cre cortices, decreas-
ing to 0.52-fold vs. controls, and to 0.24- and 0.19-fold at 5 and 6 weeks-old respectively (Fig. 2 and Table 1). 
Taurine also showed an early significant decrease in Psmc1fl/fl;CaMKIIα-Cre cortices to 0.8-fold at 4 weeks-old, 
decreasing to 0.64-fold at 5 and 6 weeks-old (Fig. 2 and Table 1). Early increases in lactate and choline-containing 
compounds were evident at 4 weeks-old to 1.28- and 1.35-fold respectively, and rose to 1.47- and 1.49-fold at 5 
weeks-old (Fig. 2 and Table 1). A significant decrease in glutamine was evident from 5 weeks-old in Psmc1fl/fl; 
CaMKIIα-Cre cortices to 0.46-fold vs. controls, and 0.22-fold at 6 weeks-old; whereas glutamate increased 1.22- 
and 1.28-fold respectively (Fig. 2 and Table 1). A late 1.16-fold increase in myo-inositol was evident at 6 weeks-old 
in Psmc1fl/fl;CaMKIIα-Cre cortices (Fig. 2 and Table 1). Except for glutamine, aspartate and alanine, all identi-
fied amino acids were increased in Psmc1fl/fl;CaMKIIα-Cre cortices at 6 weeks-old; serine and glycine signifi-
cantly increased from 5 weeks-old (Supplementary Fig. 5). Corroborative results to the cortex were obtained 
in the hippocampus, but the cerebellum did not exhibit any significant metabolic differences between Psmc1fl/fl; 
CaMKIIα-Cre and control mice up to 6 weeks-old, suggesting secondary changes in ‘other’ brain regions are not 
‘or not yet’ evident (Table 1, Supplementary Figs 4 and 6).
Early glial activation precedes neurodegeneration. Reactive gliosis, involving astrocytes and micro-
glia, is increasingly being recognised, not only as a pathological hallmark, but as a contributor to neurodegener-
ative disease and there is significant interest in identifying a metabolic signature that reflects gliosis in vivo18,19. 
We previously showed astrogliosis at 6 weeks-old in Psmc1fl/fl;CaMKIIα-Cre cortices by immunohistochemis-
try11. Here we extend our data to show reactive astrogliosis is evident from 3 weeks-old by glial fibrillary acidic 
protein (GFAP) immunostaining and immunoblotting, well before evidence of neurodegeneration (Fig. 3 and 
Supplementary Fig. 2)52. Quantitative immunoblotting analysis showed GFAP was significantly increased from 3 
weeks-old in Psmc1fl/fl;CaMKIIα-Cre cortices, and increased from 1.97- to 19.54-fold between 3 and 6 weeks-old 
(Fig. 3B and Supplementary Fig. 7). Astrocyte activation was less dramatic in the hippocampus, increasing from 
1.79- to 5.90-fold between 4 and 6 weeks-old (Fig. 3C and Supplementary Fig. 7).
Interestingly, immunohistochemistry for the ionized calcium-binding adapter molecule 1 (Iba1) microglial 
marker showed reactive microgliosis was also an early feature in Psmc1fl/fl;CaMKIIα-Cre cortices (Fig. 4). Iba1 
antibodies were not sensitive enough for immunoblotting at all ages, but semi-quantitative analysis of the immu-
nostaining showed the percentage area of the cortex stained by Iba1 in Psmc1fl/fl;CaMKIIα-Cre mice was signif-
icantly increased from 4 weeks-old, and increased from 1.92- to 3.05-fold between 4 and 6 weeks-old (Fig. 4B). 
More important, quantitation of microglial soma size revealed a significant increase from 3 weeks-old in Psmc1fl/fl; 
CaMKIIα-Cre cortices, increasing from 1.35- to 2.00-fold at 6 weeks-old (Fig. 4B). Similar changes in microglia 
were observed in Psmc1fl/fl;CaMKIIα-Cre hippocampi (Fig. 4C). Changes in microglial soma size in Psmc1fl/fl; 
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CaMKIIα-Cre mice are supported by Iba1 immunostaining showing perikaryal hypertrophy and amoeboid 
appearance with retracted processes indicative of an activated phenotype (Fig. 4A). Control microglia displayed a 
resting morphology, with smaller compact perikarya and many long thin ramified processes (Fig. 4A).
Putative metabolic changes that track gliosis. Comparisons of the trajectories of metabolite and gli-
osis changes in Psmc1fl/fl;CaMKIIα-Cre cortices may inform on putative metabolite changes that track gliosis 
(Supplementary Fig. 10). The greatly increasing trajectory of GFAP in Psmc1fl/fl;CaMKIIα-Cre cortices may cor-
relate with the significant changes in glutamate homeostasis, and possibly lactate (Figs 2 and 3). Interestingly, we 
support this by showing significantly increased levels of glutamate dehydrogenase (1.38-fold; GDH) and glycogen 
phosphorylase (1.57-fold; GPBB) in Psmc1fl/fl;CaMKIIα-Cre cortices vs. controls (Fig. 5A and Supplementary 
Fig. 8). Further, increased astrocytic GDH and GPBB immunostaining in Psmc1fl/fl;CaMKIIα-Cre cortical and 
hippocampal brain sections (Fig. 5B). In addition, GDH was associated with neuronal Lewy-like inclusions 
(Fig. 5B).
Discussion
Metabolite profiling is a more recent addition to the ‘omics’ field and gives a snapshot of a tissue’s physiology that 
may better our understanding of the multiple features of neurodegeneration. Using 400 MHz NMR spectros-
copy we have characterised the dynamic metabolic profile of cortex, hippocampus and cerebellum in Psmc1fl/fl;-
CaMKIIα-Cre mouse brain between 2 and 6 weeks-old accompanying neurodegenerative changes in this context. 
Early decreases in NAA and taurine, and increases in lactate and choline-containing compounds, were evident 
from 4 weeks-old in Psmc1fl/fl;CaMKIIα-Cre cortices. These metabolic changes were followed by decreased glu-
tamine and increased glutamate from 5 weeks-old. A late increase in myo-inositol was evident at 6 weeks-old in 
Psmc1fl/fl;CaMKIIα-Cre cortices. Metabolic differences were corroborated in the hippocampus, but not observed 
in the cerebellum up to 6 weeks-old. Differential age trajectories of key metabolites reflect the dynamic forebrain 
Figure 1. Cortex and hippocampus of Psmc1fl/fl;CaMKIIα-Cre mice display metabolic patterns distinct from 
controls. (A) PCA scores plots illustrating the difference between metabolic profiles of control and Psmc1fl/fl; 
CaMKIIα-Cre mouse hippocampi and cortices at 4 and 6 weeks-old. (B) PCA loadings from 4.14 to 0.7 ppm 
demonstrating the contribution of individual metabolites to the metabolic profiles of control and Psmc1fl/fl; 
CaMKIIα-Cre mouse hippocampi and cortices at 4 and 6 weeks-old. Positive and negative loadings indicate 
a decrease and increase in Psmc1fl/fl;CaMKIIα-Cre mice respectively. A: choline-containing compounds; B: 
taurine; C: glutamine; D: N-acetyl aspartate; E: branch-chained amino acids; F: glycine; G: creatine; H: lactate; I: 
serine; X: unknown AB system (possibly due to contamination). PCA model figures: R2X(1PC) = 0.333 (4 week-
old) and 0.581 (6 week-old) hippocampus; R2X(1PC) = 0.660 (4 week-old) and 0.740 (6 week-old) cortex.
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metabolome of Psmc1fl/fl;CaMKIIα-Cre mice. We also reveal an early significant glial response to targeted neu-
ronal dysfunction and by comparing significant metabolic changes with pathological and molecular alterations 
provide novel insights into the neuronal and glial responses to neuronal 26S proteasome dysfunction.
Interestingly, our study shows a significant decrease in cortical and hippocampal NAA levels in Psmc1fl/fl;-
CaMKIIα-Cre mice from 4 weeks-old before significant neuronal loss, indicating NAA may correlate with early 
neuronal dysfunction (Supplementary Fig. 10 A and data not shown)11,52. NAA is highly concentrated in neurons 
and as one of the most abundant metabolites in 1H MRS of the brain is employed as a non-invasive marker for 
neuronal health, providing a tool for diagnosis and evaluation of various neuropathologies in the clinical setting 
as well as the effects of potential neuroprotective therapies29–31. Numerous correlative clinical MRS studies and 
animal models have shown NAA reduction in neurodegenerative disease32–35.
The physiological functions of NAA, however, remain controversial. Substantial evidence couples NAA syn-
thesis to energy production in neuronal mitochondria and decreased NAA may reflect primarily an impaired 
mitochondrial metabolism rather than neuronal loss, suggesting that reduced NAA could simultaneously repre-
sent both neuronal dysfunction as well as death27–29. Interestingly, we found a positive correlation between NAA 
and adenosine nucleotides in Psmc1fl/fl;CaMKIIα-Cre forebrain [Spearman correlation coefficient rμμ = 0.60 (cor-
tex) and 0.74 (hippocampus), p < 0.0001]. More importantly, we recently reported that Psmc1fl/fl;CaMKIIα-Cre 
cortical neurons show early mitochondrial changes, evidenced by paranuclear aggregation of mitochondria from 
3 weeks-old52. These observations were associated with morphologically abnormal, fragmented mitochondria 
and furthermore, with decreased mitochondrial membrane potential and complex I activity52. Here we extend 
Figure 2. Differences in metabolite concentration between control and Psmc1fl/fl;CaMKIIα-Cre cortices. (A) 
Correlation plots between metabolite concentration and age expressed as % signal intensity relative to the 
total spectral area for control (black) and Psmc1fl/fl;CaMKIIα-Cre cortices (red). (B) Differences in metabolite 
concentration in Psmc1fl/fl;CaMKIIα-Cre mice expressed as fold-change vs. controls. Mean ± SEM. For A and B; 
n = Supplementary Table 1, *p < 0.002 by Man-Whitney U test.
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our previous mitochondrial analyses by quantifying the number of cytochrome oxidase IV (COXIV)-positive 
mitochondrial aggregates in Psmc1fl/fl;CaMKIIα-Cre cortical neurons between 2 and 6 weeks-old (Supplementary 
Fig. 9). We show that the number of paranuclear mitochondrial aggregates increases between 3 and 5 weeks-old, 
and then decreases at 6 weeks-old coinciding with increasing loss of neurons. The early significant decrease in 
NAA, therefore, may also be associated with changes in brain neuroenergetics, supporting the use of this metab-
olite to track neuronal health as well as death, underpinning clinical MRS studies in neurodegenerative disease 
(Supplementary Fig. 10 A and B). Increased lactate and decreased creatine also support impaired brain energy 
homeostasis in Psmc1fl/fl;CaMKIIα-Cre mice61. Given that the Psmc1fl/fl;CaMKIIα-Cre mouse model shows neu-
roinflammation and mitochondrial dysfunction accompanying neurodegeneration, features shared by multi-
ple neurodegenerative diseases, our study may provide mechanistic insight and translation relevant to diverse 
diseases.
Glutamate homeostasis is significantly altered in Psmc1fl/fl;CaMKIIα-Cre cortices and may correlate with astro-
gliosis; glutamate is increased and glutamine decreased at 5 and 6 weeks-old (Supplementary Fig. 10 C and D). 
Most 1H MRS-based metabolomic studies report a decrease in the levels of glutamate, along with NAA, in exper-
imental and clinical neurodegeneration35. Brain glutamate metabolism is complex and astrocytes play an integral 
role in the glutamate-glutamine cycle by removing glutamate from the synapse and amidating it to glutamine 
to be exported back to neurons, providing the precursor for the major excitatory and inhibitory transmitters 
glutamate and γ-aminobutyric acid62. This cycle is open, actively interfacing with other pathways, i.e. interme-
diary metabolism, and their biochemical specialisation allows astrocytes to dynamically adjust the formation of 
glutamine with the oxidation of glutamate for energy via deamination to α-ketoglutarate by GDH and entry into 
the tricarboxylic acid cycle (TCA)63. Increased astrocytic GDH in Psmc1fl/fl;CaMKIIα-Cre cortices suggests a 
shift in the metabolic fate of glutamate from conversion to glutamine towards oxidative metabolism that may be 
sustaining the energy demands of astrogliosis64. Interestingly, GDH was also associated with neuronal Lewy-like 
inclusions. It is possible that this is due to paranuclear aggregation of mitochondria in Psmc1fl/fl;CaMKIIα-Cre 
neurons52. However, GDH was recently shown to be important for oxidative metabolism of glutamine in neu-
rons during elevated energy demand65. Therefore, increased neuronal metabolism of glutamine-derived carbon 
in the TCA cycle in an attempt to support respiration may contribute to the changes in glutamate homeostasis 
in Psmc1fl/fl;CaMKIIα-Cre cortices. We cannot exclude that glutamine is also exported out of the brain into the 
circulation to maintain nitrogen levels during amino acid oxidation.
Metabolites
Cortex Hippocampus Cerebellum
4 week 5 week 6 week 4 week 5 week 6 week
6 week
FC vs. 
controls SEM
FC vs. 
controls SEM
FC vs. 
controls SEM
FC vs. 
controls SEM
FC vs. 
controls SEM
FC vs. 
controls SEM
Glutamine — 0.46 0.04 ↓Z 0.22 0.01 ↓Z 0.85 0.03 ↓ 0.31 0.05 ↓Z 0.23 0.03 ↓Z —
NAA 0.52 0.03 ↓Z 0.24 0.03 ↓Z 0.19 0.01 ↓Z 0.45 0.06 ↓ 0.44 0.01 ↓ 0.54 0.02 ↓ —
Serine — 1.24 0.04 ↑ 1.41 0.02 ↑Z — 1.27 0.05 ↑ 1.43 0.07 ↑ —
Taurine 0.80 0.01 ↓Z 0.64 0.01 ↓Z 0.64 0.01 ↓Z — 0.80 0.03 ↓ 0.80 0.03 ↓ —
Glycerol — — 1.11 0.06 ↑Z — — 1.19 0.06 ↑ —
Glycine — 1.18 0.03 ↑ 1.24 0.02 ↑ — 1.27 0.03 ↑ 1.31 0.04 ↑ —
Glutamate — 1.22 0.05 ↑ 1.28 0.03 ↑ — — — —
Creatine — — 0.75 0.02 ↓ — — 0.76 0.02 ↓ —
Leucine — — 1.43 0.04 ↑ — — 1.26 0.07 ↑ —
Phenylalanine — — 1.69 0.08 ↑ — — 1.64 0.16 ↑ —
Histidine — — 1.51 0.04 ↑ — — — —
Tyrosine — — 1.77 0.08 ↑ — — — —
Valine — — 1.87 0.09 ↑ 0.89 0.05 ↓ — 1.74 0.15 ↑ —
Isoleucine — — 1.77 0.08 ↑ 0.81 0.05 ↓ — 1.64 0.12 ↑ —
Acetate — — 0.77 0.02 ↓ — — 0.63 0.04 ↓ —
myo-Inositol — — 1.16 0.02 ↑ — — 1.26 0.05 ↑ —
Adenosine n. — — 0.71 0.02 ↓ — — 0.76 0.03 ↓ —
Choline-c. 1.35 0.03 ↑Z 1.49 0.04 ↑ — — — — —
Lactate 1.28 0.05 ↑ 1.47 0.05 ↑ — — 1.25 0.03 ↑ — —
Aspartate 1.17 0.02 ↑ — — — — 0.79 0.02 ↓ —
Alanine — — — 0.84 0.02 ↓ — — —
Table 1. Metabolic differences between control and Pmsc1fl/fl;CaMKIIα-Cre mice. Differences in metabolite 
concentration in Psmc1fl/fl;CaMKIIα-Cre mice expressed as fold-change vs. controls. Only metabolites that 
differed between control and Pmsc1fl/fl;CaMKIIα-Cre mice with a p < 0.002 by Man-Whitney U test are 
reported. Arrows indicate the direction of change in Pmsc1fl/fl;CaMKIIα-Cre mice; Z and bold arrows signify 
a positive Z-statistic. n = Supplementary Table 1. NAA, N-acetyl aspartate; Choline-c., choline-containing 
compounds.
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It is possible that astrocytes respond adaptively to the bioenergetic challenges in Psmc1fl/fl;CaMKIIα-Cre neu-
rons, leading to elevated lactate (Supplementary Fig. 10E). Intercellular metabolic coupling by the lactate shuttle 
may serve a protective function by ensuring a supply of substrates for activity in neurons, which convert lactate to 
pyruvate for oxidative metabolism. Some oxidised glutamate in astrocytes may form lactate by a partial pyruvate 
recycling pathway in Psmc1fl/fl;CaMKIIα-Cre cortices66–68. Importantly, elevated lactate in Psmc1fl/fl;CaMKIIα-Cre 
cortices may also be due to astrocytic utilisation of glucose and/or glycogen; supported by increased GPBB in 
Psmc1fl/fl;CaMKIIα-Cre astrocytes. Lactate may be transferred to neurons or used to support astrogliosis in this 
context. We note that lactate was significantly increased at 4 and 5 weeks-old, but decreased at 6 weeks-old in 
Psmc1fl/fl;CaMKIIα-Cre cortices. This is most likely explained by exhaustion of the relatively low astrocytic glyco-
gen stores in brain caused by the continuing energetic demands in Psmc1fl/fl;CaMKIIα-Cre neurons and extensive 
astrogliosis69,70.
Figure 3. Astrogliosis in Psmc1fl/fl;CaMKIIα-Cre forebrain. (A) Representative horizontal brain sections 
immunostained with glial fibrillary acidic protein (GFAP). No significant differences were evident in control 
cortices; therefore the control image is representative of all ages. Insets show the region of cortex shown 
(LHS; oval) and a higher magnification image of the neuropathological finding (RHS; white box). Scale 
bar = 500 (LHS; cortex) and 200 (RHS; hippocampus) µm. Representative immunoblots and quantification of 
GFAP in control and Psmc1fl/fl;CaMKIIα-Cre cortices (B) and hippocampi (C). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as a loading control at each age for quantification; a representative GAPDH 
is shown. Images were cropped from those shown in Supplementary Figure 7. Mean ± SEM of n = 4 mice. 
*p < 0.05, **p < 0.01 and ***p < 0.001 by unpaired Students t-test.
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The myo-inositol response in our study is surprising given the early and extensive gliosis evident in Psmc1fl/fl; 
CaMKIIα-Cre cortices (Supplementary Fig. 10F-H). Activation of glia has been associated with several metab-
olites using 1H MRS in patients and models, but changes in myo-inositol, which is mostly located in glial cells, 
are expected to represent the extent of gliosis36–39. However, more recent studies have not found an association 
between neuropathologic measures reflecting astrocyte or microglia activation and myo-inositol levels, suggesting 
that myo-inositol may not be sensitive to glial activation and mainly reflects glial cell density in line with its eleva-
tion in gliomas39,41,42. Furthermore, low baseline cortical myo-inositol levels and potential interspecies differences 
may contribute to the apparent lower sensitivity of myo-insoitol in mouse models compared to humans. It is worth 
noting that glycine significantly increased from 5 weeks-old and with age in both Psmc1fl/fl;CaMKIIα-Cre cortices 
and hippocampi, following the trajectory of GFAP (Supplementary Fig. 10I). Glycine and myo-inositol can easily 
be differentiated by in vitro 1H NMR, allowing quantitation of both metabolites here45. However, these metabolites 
cannot be reliably separated using standard clinical 1H MRS making it possible that glycine changes contribute to 
the myo-inositol-attributed gliosis signal at 3.5–3.6 ppm in humans36,37. Taken together, the use of myo-inositol as 
a gliosis marker may have limited sensitivity. Specificity and interspecies differences still require clarification, high-
lighting the need for identification of additional metabolic neuroinflammation markers.
With the exception of glutamine, most amino acids were more abundant in Psmc1fl/fl;CaMKIIα-Cre com-
pared to control cortices. The accumulation of proteasome substrates as a consequence of proteasome inhibition 
may limit critical amino acids for protein synthesis and the changes in amino acid homeostasis in Psmc1fl/fl; 
CaMKIIα-Cre mice may reflect a compensatory increase in amino acid supply across the blood brain barrier in an 
attempt to rescue the neurons71. Amino acids cannot be provided by autophagy in this context because continued 
26S proteasome dysfunction impairs autophagic degradation52. An interesting study showed that amino acid 
supplementation could rescue cell death following proteasome inhibition in yeast, mammalian cells and flies72.
Figure 4. Microgliosis in Psmc1fl/fl;CaMKIIα-Cre forebrain. (A) Representative horizontal brain sections 
immunostained with Iba1. No significant differences were evident in control cortices; therefore the control 
image is representative of all ages. Insets show the region of cortex shown (LHS; oval) and higher magnification 
images of the pathology (RHS; white boxes). Scale bar = 500 (LHS; cortex) and 200 (RHS; hippocampus) µm. 
Quantitation of microglia in control and Psmc1fl/fl;CaMKIIα-Cre cortices (B) and hippocampi (C) using the 
percentage area stained by Iba1 and microglial soma size. Left and right cortices or hippocampi of n = 3 mice at 
each age were analysed; mean ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001 by unpaired Students t-test.
www.nature.com/scientificreports/
1 0SCieNTifiC RePoRts |  (2018) 8:4833  | DOI:10.1038/s41598-018-23155-2
The significant increase in choline-containing compounds in Psmc1fl/fl;CaMKIIα-Cre cortices may be an indi-
cator of the breakdown of membrane phospholipids such as phosphatidylcholine (PtdCho). PtdCho hydrolysis by 
phospholipase A2 (PLA2) produces lyso-PtdCho, GPCh, phosphocholine and free choline. We previously showed 
PLA2 activity is increased in Psmc1fl/fl;CaMKIIα-Cre cortices, some of which is associated with the bifunctional 
enzyme peroxiredoxin 6, but other phospholipases also contribute to this activity73. Changes in choline have been 
inconsistently reported in experimental and clinical research, but several studies suggest elevated choline may 
be associated with the breakdown of neurons during the progression of neurodegenerative disease or membrane 
turnover associated with fibrillary gliosis, supporting our observations38,41,74–76.
Taurine levels were significantly decreased in Psmc1fl/fl;CaMKIIα-Cre cortices from 4 weeks-old. Taurine has 
been implicated in diverse functions in brain, but one likely rational is its role as an osmolyte, and changes in its 
concentration may indicate imbalanced ion and water homeostasis in Psmc1fl/fl;CaMKIIα-Cre cortex29,46. A recent 
study showed an inverse correlation between astrocytic activity and taurine in a mouse model of Alzheimer’s 
disease, supporting evidence that taurine may be an anti-inflammatory molecule and non-invasive marker 
of neuroinflammation in the brain77–79. Interestingly, the overall trajectory of microglial changes in Psmc1fl/fl; 
CaMKIIα-Cre cortices may be inversely associated with the trajectory of taurine, further supporting the connec-
tion to neuroinflammation of this metabolite (Supplementary Fig. 10 J and K)77–79.
Future studies using pharmacological or genetic approaches to target astroglia and microglia with comparable 
metabolomics will be of great interest to enlighten further which metabolites best represent neuroinflammation. 
Taken together, our study contributes to limited knowledge of metabolite changes during significant neuroinflam-
mation triggered as a consequence of neuronal dysfunction.
Figure 5. Increased GDH and GPBB in Psmc1fl/fl;CaMKIIα-Cre forebrain. (A) Representative immunoblots 
and quantification of GDH and GPBB in mitochondria and cytosol respectively purified from control and 
Psmc1fl/fl;CaMKIIα-Cre cortices at 6 weeks-old. Pyruvate dehydrogenase E1 component subunit alpha 
(PDHE1α; mitochondria) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; cytosol) were used as 
a loading controls. Images were cropped from those shown in Supplementary Figure 6. Mean ± SEM of n = 3 
mice. *p < 0.05 and **p < 0.01 by unpaired Students t-test. (B) Immunostaining of cortical and hippocampal 
brain sections from control and Psmc1fl/fl;CaMKIIα-Cre mice at 6 weeks-old with GDH and GPBB. Asterisks 
and arrows indicate astrocytes and Lewy-like inclusions respectively. Scale bar = 50 µm.
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